Journal of Infectious Diseases and Diagnosis

LECOM Health – Institute for Successful Aging, Erie, Pennsylvania, USA

Publications

• Research Article   
  Effect of Bamlanivimab Virus-Neutralizing Monoclonal Antibody on Hospitalization Rate and Mortality in Long Term Care Facility Residents with Recently Diagnosed Pre-Symptomatic, Mild-To-Moderate SARS-Cov2 Infection
  Author(s): Monika Murillo*, Christine Lomiguen, Mark Terrell, Ashley King Pharm, James Lin and Silvia Ferretti
  
  Objective: To measure the association between intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to Long-Term Care Facility (LTCF) residents recently diagnosed with pre-symptomatic, mild-to-moderate COVID-19 and are considered high risk for disease progression with mortality, hospitalization, and adverse effects. Design: A retrospective analysis of LTCF residents with confirmed COVID-19, pre-symptomatic, mild to moderate disease, who were treated with bamlanivimab (LY-CoV555) were compared to similar LTCF residents who did not receive monoclonal antibody treatment. Dependent variables investigated included mortality and hospitalization as primary outcomes with adverse effects as the secondary outcome. Results: A total of 107 residents from three LTCFs were diagnosed with pre-sympt.. View more»
  

  DOI: 10.35248/2576-389X.21.6.157

  Abstract HTML PDF